Literature DB >> 10372603

Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia.

J A Lieberman1.   

Abstract

It is widely accepted that schizophrenia originates from abnormalities occurring during the early stages of neural development. Although large studies have revealed behavioral precursors of schizophrenia in childhood, the disorder is usually not evident until patients are in their 20s or 30s. Some patients will be resistant to typical antipsychotic treatment at this first-onset of schizophrenia; however, treatment resistance develops in the majority of patients during the course of successive episodes. This ongoing deterioration suggests that a degenerative process operates during the active psychotic phase of the illness. This review presents evidence of neurodevelopmental and neurodegenerative mechanisms for the development of schizophrenia. These data indicate the importance of effective treatment at the first onset of schizophrenia to improve patient outcome. In addition, animal studies suggest that treatment with clozapine may prevent the neurodegenerative component responsible for the development of treatment resistance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372603

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Rationale for the study of early intervention.

Authors:  R J Wyatt; I Henter
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

2.  A Predictive Coding Account of Psychotic Symptoms in Autism Spectrum Disorder.

Authors:  Gerrit I van Schalkwyk; Fred R Volkmar; Philip R Corlett
Journal:  J Autism Dev Disord       Date:  2017-05

3.  Differential postnatal development of catecholamine and serotonin inputs to identified neurons in prefrontal cortex of rhesus monkey.

Authors:  E K Lambe; L S Krimer; P S Goldman-Rakic
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

4.  Effects of cognitive rehabilitation training on schizophrenia: 2 years of follow-up.

Authors:  Jianqing Tao; Qiang Zeng; Jia Liang; Aihua Zhou; Xuebing Yin; Ai Xu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 5.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

6.  An exploratory study from eastern India on neurological soft signs and spontaneous movement disorders in schizophrenia spectrum disorders.

Authors:  Shyamanta Das; Samrat Singh Bhandari; Simanta Talukdar; Arunima Dutta; Nabanita Barman; Dipesh Bhagabati
Journal:  Open J Psychiatry Allied Sci       Date:  2019-01-16

7.  A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes.

Authors:  T Ilani; D Ben-Shachar; R D Strous; M Mazor; A Sheinkman; M Kotler; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-09       Impact factor: 11.205

8.  Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.

Authors:  Borah Kim; Sang-Hyuk Lee; Yen Kuang Yang; Jong-Il Park; Young-Chul Chung
Journal:  Schizophr Res Treatment       Date:  2012-08-14

9.  Is there a degenerative process going on in the brain of people with Schizophrenia?

Authors:  Bjørn Rishovd Rund
Journal:  Front Hum Neurosci       Date:  2009-10-26       Impact factor: 3.169

10.  Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia.

Authors:  Annie Viala; Françoise Cornic; Marie-Noëlle Vacheron
Journal:  Schizophr Res Treatment       Date:  2012-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.